No Data
No Data
Aprea Therapeutics Doses First Patient With HPV+ HNSCC In ACESOT-1051 Trial
Aprea Therapeutics Shares Are Trading Higher After the Company Announced It Has Commenced the Dosing of Patients With HPV+ Head and Neck Squamous Cell Carcinoma in Its Ongoing ACESOT-1051 Trial.
Express News | Aprea Therapeutics Inc -Open Label Data From Study Are Expected in Second Half of 2025
Express News | Aprea Therapeutics Reports Dosing of Patient With HPV+ Head And Neck Squamous Cell Carcinoma In Ongoing ACESOT-1051 Trial
12 Health Care Stocks Moving In Monday's Pre-Market Session
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress
Unlock the Full List